Pathogenic gene for coronary artery disease
AssigneeThe Cleveland Clinic Foundation
InventorsQing Wang, Eric Topol, Lejin Wang, Chun Fan
Life of this patent
Estimating the term…
Abstract
A method of determining a person at risk of developing coronary artery disease includes detecting an alteration of at least one of an MEF2A gene, genes regulated by MEF2A transcription factor, or genes that regulate expression of MEF2A transcription factor of the patient. The alteration substantially reduces the transcription activity of the resulting MEF2A transcription factor.
Claims22
A method of identifying a person at risk of developing coronary artery disease:
- detecting an alteration of at least one of an MEF2A gene, genes regulated by MEF2A transcription factor, or genes that regulate expression of MEF2A transcription factor of the person, the alteration substantially reducing the transcription activity of the resulting MEF2A transcription factor.
A method of diagnosing an individual who has coronary artery disease or a predisposition for coronary artery disease:
- providing a nucleic acid sample from the individual, the nucleic acid comprising nucleic acid sequence corresponding to at least one of an MEF2A gene, genes regulated by MEF2A transcription factor, or genes that regulate expression of MEF2A transcription factor;
- determining if the nucliec acid sequence corresponding to at least one of an MEF2A gene, genes regulated by MEF2A transcription factor, or genes that regulate expression of MEF2A transcription factor of the patient are mutated such that the mutation impairs the transcription activation activity of a resulting MEF2A transcription factor.
A method of diagnosing an individual who has coronary artery disease or a predisposition for coronary artery disease:
- detecting mutation of the amino acid sequence the MEF2A protein encoded by the MEF2A gene, the alteration substantially reducing the transcription activity of the resulting MEF2A protein.
Dependencies are inferred from the claim text.